SMC turns down Kyprolis® and Darzalex®

The Scottish Medicines Consortium (SMC) has decided not to recommend the use of Kyprolis (carfilzomib) and Darzalex (daratumumab) as treatments for myeloma patients in Scotland. Kyprolis was considered in the relapsed and/or refractory setting for patients who have had at least one previous line of treatment in combination Revlimid® (lenalidomide) and dexamethasone but was turned…

Details